» Articles » PMID: 38962090

Interferons in Colorectal Cancer Pathogenesis and Therapy

Overview
Journal Dis Res
Date 2024 Jul 4
PMID 38962090
Authors
Affiliations
Soon will be listed here.
Abstract

As key modulators of the immune response, interferons play critical roles following infection and during the pathogenesis of cancer. The idea that these cytokines might be developed as new therapies emerged soon after their discovery. While enthusiasm for this approach to cancer therapy has waxed and waned over the ensuing decades, recent advances in cancer immunotherapy and our improved understanding of the tumor immune environment have led to a resurgence of interest in this unique class of biologic drug. Here, we review how interferons influence the growth of colorectal cancers (CRCs) and highlight new insights into how interferons and drugs that modulate interferon expression might be most effectively deployed in the clinic.

Citing Articles

Anticancer Plant Secondary Metabolites Evicting Linker Histone H1.2 from Chromatin Activate Type I Interferon Signaling.

Vlasova O, Antonova I, Magomedova K, Osipova A, Shtompel P, Borunova A Int J Mol Sci. 2025; 26(1.

PMID: 39796235 PMC: 11722331. DOI: 10.3390/ijms26010375.

References
1.
Radice E, Miranda V, Bellone G . Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. Int Immunopharmacol. 2013; 19(1):66-73. DOI: 10.1016/j.intimp.2013.12.011. View

2.
Rauch I, Rosebrock F, Hainzl E, Heider S, Majoros A, Wienerroither S . Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons. Mol Cell Biol. 2015; 35(13):2332-43. PMC: 4456449. DOI: 10.1128/MCB.01498-14. View

3.
Neurath M . Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5):329-42. DOI: 10.1038/nri3661. View

4.
Slota M, Lim J, Dang Y, Disis M . ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines. 2011; 10(3):299-306. PMC: 3360522. DOI: 10.1586/erv.10.169. View

5.
Chiriac M, Hracsko Z, Gunther C, Gonzalez-Acera M, Atreya R, Stolzer I . IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling. Gut. 2023; 73(2):282-297. PMC: 10850655. DOI: 10.1136/gutjnl-2023-329628. View